{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:28:19Z","timestamp":1791185299156,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00280-014-2525-6","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T12:02:37Z","timestamp":1406030557000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia"],"prefix":"10.1007","volume":"74","author":[{"given":"Quentin","family":"Chalret du Rieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"White-Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Picaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","volume":"16","author":"C Cao","year":"2009","unstructured":"Cao C, Yan TD, Black D, Morris DL (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:2152\u20132165","journal-title":"Ann Surg Oncol"},{"key":"2525_CR2","first-page":"3380","volume":"49","author":"G Los","year":"1989","unstructured":"Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380\u20133384","journal-title":"Cancer Res"},{"key":"2525_CR3","doi-asserted-by":"crossref","unstructured":"Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 10:915\u201333, xi","DOI":"10.1016\/S1055-3207(18)30039-5"},{"key":"2525_CR4","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116:5608\u20135618","journal-title":"Cancer"},{"key":"2525_CR5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.soc.2012.07.014","volume":"21","author":"D Elias","year":"2012","unstructured":"Elias D, Quenet F, Goere D (2012) Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21:611\u2013623","journal-title":"Surg Oncol Clin N Am"},{"key":"2525_CR6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Morice P, Pomel C, Pocard M, Guyon F, Porcheron J, Glehen O (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39:1435\u20131443","journal-title":"Eur J Surg Oncol"},{"key":"2525_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, Turco LC, Piovano E, Scambia G (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case\u2013control study on survival in patients with 2\u00a0year follow-up. Gynecol Oncol 127:502\u2013505","journal-title":"Gynecol Oncol"},{"key":"2525_CR8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575\u20131581","journal-title":"Ann Surg Oncol"},{"key":"2525_CR9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/00912709922007967","volume":"39","author":"HK Cho","year":"1999","unstructured":"Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD (1999) Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39:394\u2013401","journal-title":"J Clin Pharmacol"},{"key":"2525_CR10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","volume":"43","author":"MA Steller","year":"1999","unstructured":"Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL (1999) A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 43:106\u2013114","journal-title":"Cancer Chemother Pharmacol"},{"key":"2525_CR11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","volume":"15","author":"E Bree de","year":"2008","unstructured":"de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD (2008) Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 15:1183\u20131192","journal-title":"Ann Surg Oncol"},{"key":"2525_CR12","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jss.2012.01.015","volume":"179","author":"K Votanopoulos","year":"2013","unstructured":"Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179:e133\u2013e139","journal-title":"J Surg Res"},{"key":"2525_CR13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","volume":"7","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Stuart OA, Chang D, Sugarbaker PH (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7:596\u2013603","journal-title":"Anticancer Drugs"},{"key":"2525_CR14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/02656730310001637325","volume":"20","author":"D Atallah","year":"2004","unstructured":"Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM (2004) Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperth 20:405\u2013419","journal-title":"Int J Hyperth"},{"key":"2525_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267\u2013272","journal-title":"Ann Oncol"},{"key":"2525_CR16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","volume":"60","author":"CR Culy","year":"2000","unstructured":"Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895\u2013924","journal-title":"Drugs"},{"key":"2525_CR17","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdh398","volume":"15","author":"D Elias","year":"2004","unstructured":"Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558\u20131565","journal-title":"Ann Oncol"},{"key":"2525_CR18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00280-007-0654-x","volume":"62","author":"G Ferron","year":"2008","unstructured":"Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I, Chatelut E (2008) Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol 62:679\u2013683","journal-title":"Cancer Chemother Pharmacol"},{"key":"2525_CR19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-012-2060-2","volume":"71","author":"C Perez-Ruixo","year":"2013","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farre-Alegre J, Perez-Ruixo JJ (2013) Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Cancer Chemother Pharmacol 71:693\u2013704","journal-title":"Cancer Chemother Pharmacol"},{"key":"2525_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1208\/s12248-010-9249-2","volume":"13","author":"B Valenzuela","year":"2011","unstructured":"Valenzuela B, Nalda-Molina R, Bretcha-Boix P, Escudero-Ortiz V, Duart MJ, Carbonell V, Sureda M, Rebollo JP, Farre J, Brugarolas A, Perez-Ruixo JJ (2011) Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J 13:72\u201382","journal-title":"AAPS J"},{"key":"2525_CR21","doi-asserted-by":"crossref","unstructured":"Perez-Ruixo C, Peris JE, Escudero-Ortiz V, Bretcha-Boix P, Farre-Alegre J, Perez-Ruixo JJ, Valenzuela B (2014) Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients. Cancer Chemother Pharmacol\u00a073(5):1009\u20131020","DOI":"10.1007\/s00280-014-2436-6"},{"key":"2525_CR22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40262-013-0092-3","volume":"52","author":"C Perez-Ruixo","year":"2013","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farre-Alegre J, Perez-Ruixo JJ (2013) Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin. Clin Pharmacokinet 52:1111\u20131125","journal-title":"Clin Pharmacokinet"},{"key":"2525_CR23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejso.2006.03.004","volume":"32","author":"D Elias","year":"2006","unstructured":"Elias D, Raynard B, Bonnay M, Pocard M (2006) Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol 32:607\u2013613","journal-title":"Eur J Surg Oncol"},{"key":"2525_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0006-2944(77)90089-8","volume":"18","author":"AF LeRoy","year":"1977","unstructured":"LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184\u2013191","journal-title":"Biochem Med"},{"key":"2525_CR25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.2011.557","volume":"106","author":"B Royer","year":"2012","unstructured":"Royer B, Kalbacher E, Onteniente S, Jullien V, Montange D, Piedoux S, Thiery-Vuillemin A, Delroeux D, Pili-Floury S, Guardiola E, Combe M, Muret P, Nerich V, Heyd B, Chauffert B, Kantelip JP, Pivot X (2012) Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study. Br J Cancer 106:460\u2013467","journal-title":"Br J Cancer"},{"key":"2525_CR26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","volume":"57","author":"S Urien","year":"2004","unstructured":"Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756\u2013763","journal-title":"Br J Clin Pharmacol"},{"key":"2525_CR27","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036\u20132049","journal-title":"Pharm Res"},{"key":"2525_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10928-009-9143-7","volume":"37","author":"K Brendel","year":"2010","unstructured":"Brendel K, Comets E, Laffont C, Mentre F (2010) Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn 37:49\u201365","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2525_CR29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11:558\u2013569","journal-title":"AAPS J"},{"key":"2525_CR30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359\u2013374","journal-title":"Cancer Treat Res"},{"key":"2525_CR31","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205\u20131218","journal-title":"Clin Cancer Res"},{"key":"2525_CR32","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/01.cad.0000176505.94175.d4","volume":"16","author":"B Royer","year":"2005","unstructured":"Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X (2005) Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 16:1009\u20131016","journal-title":"Anticancer Drugs"},{"key":"2525_CR33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-007-0484-x","volume":"61","author":"B Royer","year":"2008","unstructured":"Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X (2008) Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol 61:415\u2013421","journal-title":"Cancer Chemother Pharmacol"},{"key":"2525_CR34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90:154\u2013166","journal-title":"Comput Methods Programs Biomed"},{"key":"2525_CR35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00228-008-0511-9","volume":"64","author":"H Mahteme","year":"2008","unstructured":"Mahteme H, Wallin I, Glimelius B, Pahlman L, Ehrsson H (2008) Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol 64:907\u2013911","journal-title":"Eur J Clin Pharmacol"},{"key":"2525_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0091270009360980","volume":"51","author":"E Cotte","year":"2011","unstructured":"Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, Glehen O, Tod M (2011) Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol 51:9\u201318","journal-title":"J Clin Pharmacol"},{"key":"2525_CR37","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/annonc\/mds074","volume":"23","author":"DL Jardim","year":"2012","unstructured":"Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM (2012) Oxaliplatin-related thrombocytopenia. Ann Oncol 23:1937\u20131942","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2525-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2525-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2525-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T22:40:50Z","timestamp":1565649650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2525-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2525-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}